Mankind Pharma

The capital raised through this pledge is expected to support Mankind Pharma's strategic initiatives and growth plans

Mankind Pharma declared its September quarter numbers on Tuesday after market hours

Mankind's revenue from operations rose to Rs 3,077 crore in Q2 FY25, a 13.6 per cent Y-o-Y rise from Rs 2,708 crore reported in Q2 FY24

The company, which also makes Manforce condoms and Prega News pregnancy kits, said its consolidated net profit rose to RS 653 crore for the quarter ended Sep 30, a 30% climb from last year

Nuvama Alternative & Quantitative Research in its early predictions on AMFI semi-annual categorization expects RVNL, Polycab India and 5 other stocks to be upgraded to large-caps.

The announcement was made after market hours. On Wednesday, Mankind Pharma's shares closed at Rs 2,529.80 apiece, down 1.46 per cent on the Bombay Stock Exchange (BSE)

Here is the complete list of stocks exiting their IPO lock-in period between October 8, 2024, and December 31, 2024

Stocks to watch: SBI plans to open 600 new branches this fiscal year to expand its reach in emerging residential areas, said its chairman and managing director CS Setty.

Mankind Pharma, which has brands including Manforce condoms and Prega News pregnancy tests, signed an agreement to acquire Bharat Serums

Mankind Pharma on Monday said it will raise up to Rs 10,000 crore via issuance of non-convertible debentures and commercial papers. The company said its board has approved to raise up to Rs 5,000 crore via non-convertible debentures in 3-4 distinct series with maturities of up to 48 months. The board's fundraising committee also approved to raise up to Rs 5,000 crore via listed and rated commercial papers, having face value as may be decided in accordance with applicable law, in one or more tranches or series, the drug maker said in a regulatory filing. The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,630 crore. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and consumer healthcare products. Shares of the company on Monday ended 2.68 per cent down at Rs .

Mankind Pharma approved raising Rs 10,000 crore via the issuance of Non-Convertible Debentures (NCD) and Commercial Papers (CP)

The board announced the issuance of corporate guarantees for four of its subsidiaries, namely Mankind Agritech, Appian Properties, Copmed Pharmaceuticals, and Lifestar Pharma.

The board is to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof.

Mankind Pharma share price surged after the company on Tuesday completed a business transfer agreement (BTA) to shift its over-the-counter (OTC) business to its wholly owned subsidiary

Mankind Pharma is likely to raise Rs 9,000 crore through NCDs to acquire Bharat Serums and Vaccines

The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure

The acquisition of Bharat Serums and Vaccines would add a lot of value, aiding future growth of Mankind Pharma, according to Vice Chairman and Managing Director Rajeev Juneja. On July 25, Mankind had announced that it will fully acquire Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of around Rs 13,630 crore. "One thing should be very clear, this acquisition is not to really add some kind of revenue, but to add a lot of value, future growth, entry barrier, super specialty business in Mankind," Juneja said in an analyst call. Whatever the company is paying for BSV, it is very relevant as the company has "so much of value" with well established business, he said. The acquisition is in line with the company's strategy of buying high entry barrier businesses, he stated. The buyout will solidify Mankind's position with complementary drug portfolio and extensive reach to target rapidly growing highly under-penetrated markets, especially in fertility,

Mankind also announced a rise in its prescriber penetration to 83.2 per cent in Q1 FY25, from 82.7 per cent in the same quarter last financial year

'We don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity'

Deal opens doors to overseas markets with low competition